Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors associated with liver fibrosis onset and progression. However, little is known about biochemical factors predicting liver fibrosis evolution in large NAFLD populations.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Patients aged 18 years old or more
* Patients with at least on of the following metabolic disorders
* Obesity
* Diabetes
* Arterial hypertension
* Dyslipidemia
Exclusion Criteria:
* Average daily consumption of alcohol \>20 g in women and of \>30 g in men (assessed by Alcohol Use Disorders Identification Test, AUDIT;
* presence of hepatitis B surface antigen and antibody to hepatitis C virus;
* positive tests for autoimmune hepatitis;
* cirrhosis and other chronic liver diseases;
* diagnosis of oncological diseases
* concomitant therapy with drugs known to promote liver steatosis (e.g. amiodarone);
* other chronic infectious or autoimmune disease;
Primary outcome measure(s)
Clinical, biochemical and genetic factors associated to progression of liver fibrosis in a large cohort of patients with NAFLD — Patients will be followed for an expected mean time of 120 months To detect non conventional factors associated with the progression of liver fibrosis in patients with NAFLD. Progression of liver fibrosis will be assessed by non invasive markers (such as FIB-4, Nafld Fibrosis Score e liver elastography). The predictive role of the following factors will be assessed: plasmatic and urinary isoprostanes, thromboxane, platelet recruitment, reactive species of oxygen, nadph oxidase (nox2). Genes of interested will be sequenced.
Trial sites (1)
Facility
City
Region
Status
Day Service of Internal Medicine and Metabolic Disorders - Policlinico Umberto I - Sapienza University of Rome
Rome
Italy
Recruiting
More University of Roma La Sapienza trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
